Astec Lifesciences Share Price
Sector: Chemical Manufacturing
698.00 -13.30 (-1.87%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
698.00
Today’s High
719.25
52 Week Low
635.95
52 Week High
1487.65
701.25 -11.35 (-1.59%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
697.95
Today’s High
723.25
52 Week Low
634.60
52 Week High
1474.40
Key Metrics
- Market Cap (In Cr) 1368.22
- Beta 0.97
- Div. Yield (%) 0
- P/B 5.95
- TTM P/E -
- Peg Ratio -
- Sector P/E 17.01
- D/E 0.02
- Open Price 706
- Prev Close 711.3
Astec Lifesciences Analysis
Price Analysis
-
1 Week3.06%
-
3 Months0.33%
-
6 Month-32.48%
-
YTD-28.69%
-
1 Year-38.98%
Risk Meter
- 55% Low risk
- 55% Moderate risk
- 55% Balanced Risk
- 55% High risk
- 55% Extreme risk
Astec Lifesciences News
Q4 results today: LTIMindtree, Tata Consumer, Bajaj Housing to declare earnings
2 min read . 23 Apr 2025Godrej Enterprises looks for a brand repositioning, adopts new logo
3 min read . 28 Nov 2024Astec Lifesciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 381.3
- Selling/ General/ Admin Expenses Total
- 61.1
- Depreciation/ Amortization
- 43.71
- Other Operating Expenses Total
- 89.47
- Total Operating Expense
- 491.22
- Operating Income
- -109.92
- Net Income Before Taxes
- -140.99
- Net Income
- -134.75
- Diluted Normalized EPS
- -68.71
- Period
- 2025
- Total Assets
- 881.42
- Total Liabilities
- 646.68
- Total Equity
- 234.75
- Tangible Book Valueper Share Common Eq
- 107.74
- Period
- 2025
- Cashfrom Operating Activities
- -8.4
- Cashfrom Investing Activities
- -15.23
- Cashfrom Financing Activities
- 23.73
- Net Changein Cash
- 0.1
- Period
- 2024
- Total Revenue
- 458.18
- Selling/ General/ Admin Expenses Total
- 90.91
- Depreciation/ Amortization
- 36.94
- Other Operating Expenses Total
- 7.88
- Total Operating Expense
- 500.24
- Operating Income
- -42.05
- Net Income Before Taxes
- -61.75
- Net Income
- -46.93
- Diluted Normalized EPS
- -23.9
- Period
- 2024
- Total Assets
- 974.93
- Total Liabilities
- 605.64
- Total Equity
- 369.29
- Tangible Book Valueper Share Common Eq
- 178.42
- Period
- 2024
- Cashfrom Operating Activities
- 10.22
- Cashfrom Investing Activities
- -135.18
- Cashfrom Financing Activities
- 148.16
- Net Changein Cash
- 0
- Period
- 2023
- Total Revenue
- 628.17
- Selling/ General/ Admin Expenses Total
- 83.13
- Depreciation/ Amortization
- 33.65
- Other Operating Expenses Total
- 8.15
- Total Operating Expense
- 585.04
- Operating Income
- 43.13
- Net Income Before Taxes
- 34.95
- Net Income
- 25.56
- Diluted Normalized EPS
- 13.23
- Period
- 2023
- Total Assets
- 979.41
- Total Liabilities
- 560.05
- Total Equity
- 419.36
- Tangible Book Valueper Share Common Eq
- 205.79
- Period
- 2023
- Cashfrom Operating Activities
- 74.66
- Cashfrom Investing Activities
- -112.51
- Cashfrom Financing Activities
- 37.77
- Net Changein Cash
- -0.08
- Period
- 2022
- Total Revenue
- 676.57
- Selling/ General/ Admin Expenses Total
- 73.13
- Depreciation/ Amortization
- 34.36
- Other Operating Expenses Total
- 8.74
- Total Operating Expense
- 556.85
- Operating Income
- 119.72
- Net Income Before Taxes
- 121.13
- Net Income
- 89.86
- Diluted Normalized EPS
- 45.84
- Period
- 2022
- Total Assets
- 896.76
- Total Liabilities
- 500.26
- Total Equity
- 396.5
- Tangible Book Valueper Share Common Eq
- 196.51
- Period
- 2022
- Cashfrom Operating Activities
- 23.6
- Cashfrom Investing Activities
- -103.87
- Cashfrom Financing Activities
- 80.48
- Net Changein Cash
- 0.22
- Period
- 2021
- Total Revenue
- 554.87
- Selling/ General/ Admin Expenses Total
- 58.78
- Depreciation/ Amortization
- 25.66
- Other Operating Expenses Total
- 6.81
- Total Operating Expense
- 468.95
- Operating Income
- 85.92
- Net Income Before Taxes
- 89.07
- Net Income
- 65.05
- Diluted Normalized EPS
- 33.21
- Period
- 2021
- Total Assets
- 677.59
- Total Liabilities
- 368.41
- Total Equity
- 309.18
- Tangible Book Valueper Share Common Eq
- 155.21
- Period
- 2021
- Cashfrom Operating Activities
- -8.2
- Cashfrom Investing Activities
- -73.11
- Cashfrom Financing Activities
- 81.34
- Net Changein Cash
- 0.03
- Period
- 2020
- Total Revenue
- 522.61
- Selling/ General/ Admin Expenses Total
- 49.53
- Depreciation/ Amortization
- 23.16
- Other Operating Expenses Total
- 11.77
- Total Operating Expense
- 460.41
- Operating Income
- 62.19
- Net Income Before Taxes
- 61.35
- Net Income
- 47.51
- Diluted Normalized EPS
- 24.34
- Period
- 2020
- Total Assets
- 571.72
- Total Liabilities
- 325.15
- Total Equity
- 246.57
- Tangible Book Valueper Share Common Eq
- 124.18
- Period
- 2020
- Cashfrom Operating Activities
- 168.44
- Cashfrom Investing Activities
- -73.81
- Cashfrom Financing Activities
- -94.53
- Net Changein Cash
- 0.1
- Period
- 2025-03-31
- Total Revenue
- 119.53
- Selling/ General/ Admin Expenses Total
- 14.43
- Depreciation/ Amortization
- 11.58
- Other Operating Expenses Total
- 26.04
- Total Operating Expense
- 125.58
- Operating Income
- -6.05
- Net Income Before Taxes
- -15.66
- Net Income
- -16.09
- Diluted Normalized EPS
- -8.2
- Period
- 2025-03-31
- Total Assets
- 881.42
- Total Liabilities
- 646.68
- Total Equity
- 234.75
- Tangible Book Valueper Share Common Eq
- 107.74
- Period
- 2025-03-31
- Cashfrom Operating Activities
- -8.4
- Cashfrom Investing Activities
- -15.23
- Cashfrom Financing Activities
- 23.73
- Net Changein Cash
- 0.1
- Period
- 2024-12-31
- Total Revenue
- 93.86
- Selling/ General/ Admin Expenses Total
- 15.52
- Depreciation/ Amortization
- 11.4
- Other Operating Expenses Total
- 22.5
- Total Operating Expense
- 111
- Operating Income
- -17.14
- Net Income Before Taxes
- -25.15
- Net Income
- -40.38
- Diluted Normalized EPS
- -20.59
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 98.55
- Selling/ General/ Admin Expenses Total
- 14.93
- Depreciation/ Amortization
- 11.47
- Other Operating Expenses Total
- 23.12
- Total Operating Expense
- 129.75
- Operating Income
- -31.21
- Net Income Before Taxes
- -38.54
- Net Income
- -38.56
- Diluted Normalized EPS
- -19.66
- Period
- 2024-09-30
- Total Assets
- 882.1
- Total Liabilities
- 590.6
- Total Equity
- 291.5
- Tangible Book Valueper Share Common Eq
- 137.97
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 23.84
- Cashfrom Investing Activities
- -14.48
- Cashfrom Financing Activities
- -9.79
- Net Changein Cash
- -0.43
- Period
- 2024-06-30
- Total Revenue
- 69.37
- Selling/ General/ Admin Expenses Total
- 16.23
- Depreciation/ Amortization
- 9.27
- Other Operating Expenses Total
- 17.81
- Total Operating Expense
- 124.89
- Operating Income
- -55.52
- Net Income Before Taxes
- -61.64
- Net Income
- -39.72
- Diluted Normalized EPS
- -20.26
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 153.75
- Selling/ General/ Admin Expenses Total
- 14.69
- Depreciation/ Amortization
- 9.01
- Other Operating Expenses Total
- 20.92
- Total Operating Expense
- 149.94
- Operating Income
- 3.81
- Net Income Before Taxes
- -0.93
- Net Income
- -0.97
- Diluted Normalized EPS
- -0.46
- Period
- 2024-03-31
- Total Assets
- 974.93
- Total Liabilities
- 605.64
- Total Equity
- 369.29
- Tangible Book Valueper Share Common Eq
- 178.42
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 8.57
- Cashfrom Investing Activities
- -135.18
- Cashfrom Financing Activities
- 148.16
- Net Changein Cash
- 0
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Astec Lifesciences Technical
Moving Average
SMA
- 5 Day711.85
- 10 Day684.78
- 20 Day701.06
- 50 Day702.78
- 100 Day836.06
- 300 Day989.86
Astec Lifesciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Excel Industries
- 1111
- -28.7
- -2.52
- 1745
- 798.5
- 1396.61
- 3b Blackbio Dx
- 1697.2
- 3.55
- 0.21
- 2350
- 765
- 1460.73
- Astec Lifesciences
- 698
- -13.3
- -1.87
- 1487.65
- 635.95
- 1368.22
- Punjab Chemicals And Crop Prot
- 1132.55
- -18.25
- -1.59
- 1575
- 669.55
- 1387.21
- Paushak
- 4638.45
- 38.5
- 0.84
- 6385
- 3746
- 1429.62
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Excel Industries
- 17.28
- 0.93
- 7.13
- 8.6
- 3b Blackbio Dx
- 45.37
- 6.54
- 33.47
- 44.85
- Astec Lifesciences
- -
- 6.1
- -0.07
- -0.04
- Punjab Chemicals And Crop Prot
- 34.05
- 3.92
- 23.61
- 6.43
- Paushak
- 28.86
- 3.06
- 13.8
- 25.27
Astec Lifesciences Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 23-Apr-25
- Audited Results
- 27-Jan-25
- Quarterly Results
- 25-Oct-24
- Quarterly Results
- 29-Jul-24
- Quarterly Results
- 02-May-24
- Audited Results
- 25-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results & Others
- 27-Jul-23
- Quarterly Results
- 02-May-23
- Audited Results & Final Dividend
- 30-Jan-23
- Quarterly Results & Others
- Meeting Date
- Announced on
- Purpose
- 28-Jul-25
- 23-Apr-25
- AGM
- 01-Jun-25
- 28-Apr-25
- POM
- 18-Mar-25
- 11-Feb-25
- POM
- 16-Dec-24
- 13-Nov-24
- POM
- 29-Jul-24
- 02-May-24
- AGM
- 10-Mar-24
- 07-Feb-24
- POM
- 27-Jul-23
- 02-May-23
- AGM
- 25-Jul-22
- 02-May-22
- AGM
- 28-Jul-21
- 30-Apr-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 02-May-23
- -
- 21-Jul-23
- 1.5
- 02-May-22
- -
- 19-Jul-22
- 1.5
- 30-Apr-21
- -
- 22-Jul-21
- 1.5


